Updates in antithrombotic therapy in coronary and peripheral artery disease

Area of Science:

• Cardiology
• Vascular Medicine
• Pharmacology

Background:

• Atherosclerotic cardiovascular disease (ASCVD) includes coronary artery disease (CAD) and peripheral artery disease (PAD), often coexisting.
• Platelet activation and thrombin generation are key pathophysiological mechanisms in acute ischemic events within ASCVD.
• Dual-pathway inhibition, a combination of antiplatelet and antithrombotic agents, is an emerging strategy for managing ASCVD.

Purpose of the Study:

• To review the role of dual-pathway inhibition in improving cardiovascular outcomes for patients with ASCVD.
• To identify patients with CAD and PAD who may benefit from dual-pathway inhibition.
• To provide an overview of the clinical presentations of stable CAD and lower extremity PAD.

Main Methods:

• Literature review focusing on dual-pathway inhibition in ASCVD.
• Analysis of studies evaluating antiplatelet and antithrombotic therapy combinations.
• Synthesis of clinical data on CAD and PAD presentations.

Main Results:

• Dual-pathway inhibition demonstrates potential for improving cardiovascular outcomes in ASCVD patients.
• Understanding patient profiles with coexisting CAD and PAD is crucial for treatment selection.
• Clinical presentations of CAD and PAD inform therapeutic strategies.

Conclusions:

• Dual-pathway inhibition is a promising therapeutic approach for select ASCVD patients.
• Personalized treatment strategies considering coexisting CAD and PAD are essential.
• Further research may refine patient selection for dual-pathway inhibition.